Monitor for the initiation of the pivotal registrational trial in advanced ovarian cancer, which is the next major catalyst. The $26.9M cash position provides runway into late 2026, but the company will likely need additional funding to complete a registrational trial. Watch for updates on the Phase 2 ovarian cancer data and any new financing announcements.
Price Chart
Executive Summary
Allarity Therapeutics reported Q2 2026 results with a net loss of $3.4M (vs $2.3M in Q2 2025), driven by higher interest expense and a derivative liability charge. Cash and restricted cash totaled $26.9M at quarter-end, up from $14.7M a year ago, providing runway into late 2026. Key operational milestones include a USPTO patent for the stenoparib DRP companion diagnostic (exclusivity to 2042), CLIA certification of its in-house lab, and completion of the Phase 3 manufacturing campaign.
Key Financial Metrics
Key Facts
- Q2 2026 net loss of $3.4M, compared to $2.3M in Q2 2025
- Cash and restricted cash of $26.9M as of June 30, 2026, vs $14.7M at June 30, 2025
- R&D expenses fell to $1.3M in Q2 2026 from $2.3M in Q2 2025
- G&A expenses fell to $1.3M in Q2 2026 from $1.8M in Q2 2025
- USPTO granted key U.S. patent for stenoparib DRP companion diagnostic, with exclusivity into April 2042
- Obtained CLIA certification for in-house laboratory in Hørsholm, Denmark
- Completed Phase 3 API manufacturing campaign in July 2026, ahead of schedule
- AACR 2026 data linked higher stenoparib DRP scores with enhanced overall survival in advanced ovarian cancer
- Phase 2 trial in advanced ovarian cancer and SCLC combination trial continued enrollment
- Total comprehensive loss attributable to common stockholders was $3.7M for Q2 2026, vs $4.2M in Q2 2025
Financial Impact
Q2 2026 net loss of $3.4M; cash and restricted cash of $26.9M; R&D expenses $1.3M; G&A expenses $1.3M; total comprehensive loss $3.7M
Risk Factors
- Clinical-stage company with no approved products; reliance on stenoparib's success
- Cash runway limited to approximately 10 quarters at current burn rate; potential need for dilutive financing
- Regulatory uncertainty regarding DRP companion diagnostic and FDA approval path
- Competition from other PARP inhibitors and WNT pathway inhibitors
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345276 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $1.04 | awaiting T+20 | — | $0.9200 (−11.54%) |
Sep 29, 2026 28d ago | 8-K | $0.9651 $0.9200 | ▼ −4.67% | ▼ −5.39% | $0.9200 (−4.67%) |
Sep 28, 2026 29d ago | Press Release | $0.9684 $0.9151 | ▼ −5.50% | ▼ −5.47% | $0.9200 (−5.00%) |
Sep 16, 2026 5w ago | 8-K | $1.16 $0.8699 | ▼ −24.68% | ▼ −27.86% | $0.9200 (−20.35%) |
Sep 14, 2026 6w ago | 8-K | $1.17 $0.8601 | ▼ −26.49% | ▼ −28.75% | $0.9200 (−21.37%) |
Sep 11, 2026 6w ago | Press Release | $1.22 $0.9900 | ▼ −18.85% | ▼ −20.72% | $0.9200 (−24.59%) |
Aug 14, 2026 10w ago | Press Release | $1.37 $1.17 | ▼ −14.60% | ▼ −12.61% | $0.9200 (−32.85%) |
Jul 1, 2026 16w ago | 8-K | $1.33 $1.16 | ▼ −12.78% | ▼ −10.60% | $0.9200 (−30.83%) |
Jun 22, 2026 18w ago | 8-K | $1.36 $1.19 | ▼ −12.50% | ▼ −12.35% | $0.9200 (−32.35%) |
Jun 18, 2026 18w ago | Press Release | $1.43 $1.17 | ▼ −18.18% | ▼ −18.71% | $0.9200 (−35.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers